Mulenga, J., Allen, S., Stevens, W., Kamali, A., Hughes, P., Kaleebu, P., Birungi, J., Karita, E., Stevens, G., Anzala, O., Dally, L., Farah, B., Fast, P., Gilmour, J., Jaoko, W., Ketter, N., Manigart, O., Price, M.A., Sanders, E.J., Stoll-Johnson, L., Yates, S., Bahemuka, U., Bwanika, A., Ruzagira, E., Kayitenkore, K., Amornkul, P., Awuondo, K., Mutua, G., Mwangome, M., Nanvubya, A., Omosa, G., Scott, J., Shutes, E.
The objective of this study was to establish clinical laboratory reference intervals for 25 hematology, immunology and biochemistry values among healthy African adults typical of those who might join a clinical trial. It is concluded that to accelerate clinical trials in Africa, and to improve their scientific validity, locally appropriate reference ranges should be used. This study in Uganda, Kenya and Zambia provides ranges that will inform inclusion criteria and evaluation of adverse events for studies in these regions of Africa.
PLoS ONE (2009) 4 (2): e4401. [doi:10.1371/journal.pone.0004401]